title: [Pilot study of Ginkgolide B, a PAF-acether specific inhibitor in the treatment of acute outbreaks of multiple sclerosis].
abstract: Ten patients with relapsing-remitting multiple sclerosis in acute relapse were treated with a five-day course of intravenous ginkgolide B, a specific inhibitor of PAF-acether. Eight patients had improvement of their neurological score, beginning 2 to 6 days after the initiation of therapy. This improvement was sustained in 5 patients and only transient in 3. Two out of these 3 patients with secondary failure and the other 2 who did not respond to ginkgolide therapy, received i.v. methylprednisolone. Three patients experienced mild side effects under ginkgolide therapy but none of the patients had any serious adverse effect. A controlled randomized study is underway, in order to confirm these results and test higher dosages and more prolonged administration.
authors.affiliation: Clinique et Service Universitaires de Neurologie, Hôpital Pellegrin, Bordeaux, France.
authors.forename: B
authors.initials: B
authors.lastname: Brochet
authors.forename: J M
authors.initials: JM
authors.lastname: Orgogozo
authors.forename: P
authors.initials: P
authors.lastname: Guinot
authors.forename: J F
authors.initials: JF
authors.lastname: Dartigues
authors.forename: P
authors.initials: P
authors.lastname: Henry
authors.forename: P
authors.initials: P
authors.lastname: Loiseau
mesh_terms: D000328:Adult; D004224:Diterpenes; D005260:Female; D046934:Ginkgolides; D006801:Humans; D007783:Lactones / Q000627:therapeutic use*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy*; D009460:Neurologic Examination; D010865:Pilot Projects; D010972:Platelet Activating Factor / Q000037:antagonists & inhibitors*
chemical_list: D004224:Diterpenes; D046934:Ginkgolides; D007783:Lactones; D010972:Platelet Activating Factor; C045856:ginkgolide B
vernacular_title: Etude pilote d'un inhibiteur spécifique du PAF-acéther, le ginkgolide B dans le traitement des poussées aiguës de sclérose en plaques.